Skip to main content
Clinical Trials/NL-OMON34092
NL-OMON34092
Completed
Phase 4

PE-Prove Study PROMUS* Element* Everolimus-Eluting Coronary Stent System European Post-Approval Surveillance Study A prospective, open label, multi-center observational study - PE-Prove study

Boston Scientific International S.A.0 sites90 target enrollmentTBD

Overview

Phase
Phase 4
Intervention
Not specified
Conditions
Not specified
Sponsor
Boston Scientific International S.A.
Enrollment
90
Status
Completed
Last Updated
last year

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
TBD
End Date
TBD
Last Updated
last year
Study Type
Observational invasive

Investigators

Sponsor
Boston Scientific International S.A.

Eligibility Criteria

Inclusion Criteria

  • All patients who are candidates for Coronary artery stenting, signed the Informed Consent Form and are eligible to receive a PROMUS\* Element\* stent will be evaluated for enrollment in this study.

Exclusion Criteria

  • No study\-specific exclusion criteria apart from any contra\-indications
  • Page 20\-21 protocol

Outcomes

Primary Outcomes

Not specified

Similar Trials